Last $1,325 MXN
Change Today +25.00 / 1.92%
Volume 11.9K
GILD* On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 4:09 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

gilead sciences inc (GILD*) Snapshot

Open
$1,335
Previous Close
$1,300
Day High
$1,335
Day Low
$1,318
52 Week High
08/20/14 - $1,335
52 Week Low
08/23/13 - $770.40
Market Cap
2.0T
Average Volume 10 Days
5.0K
EPS TTM
--
Shares Outstanding
1.5B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GILEAD SCIENCES INC (GILD*)

gilead sciences inc (GILD*) Details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.

6,100 Employees
Last Reported Date: 02/25/14
Founded in 1987

gilead sciences inc (GILD*) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.6M
President and Chief Operating Officer
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $746.2K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $884.2K
Senior Advisor
Total Annual Compensation: $810.4K
Compensation as of Fiscal Year 2013.

gilead sciences inc (GILD*) Key Developments

Gilead Sciences Licenses Tenofovir Alafenamide to Medicines Patent Pool

Gilead Sciences has announced the licensing of its candidate drug tenofovir alafenamide (TAF) to the Medicines Patent Pool. The drug is currently in development for the treatment of HIV and hepatitis B virus (HBV) infections and its inclusion is contingent upon US regulatory approval. Should these conditions be met, the licence will allow generics manufacturers based in India and China to apply for licences to manufacture and distribute the drug to 112 developing countries.

European CHMP Adopts Positive Opinion for Gilead's Zydelig (delalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

Gilead Sciences Inc. announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Zydelig(R) (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin lymphoma (iNHL). The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy or, as first-line treatment in CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy and also as monotherapy for the treatment of adult patients with FL that is refractory to two prior lines of treatment. The CHMP's recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union (EU). CLL and FL are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infection and bone marrow failure requiring treatment. Relapse commonly occurs after initial chemo-immunotherapy and many patients with relapsed CLL or FL are unable to tolerate chemotherapy, which may limit their treatment options. The CHMP positive opinion for Zydelig is based on data from two clinical trials -- Study 116 and Study 101-09. Study 116, a pivotal Phase 3 trial, investigated the efficacy and safety of Zydelig in combination with rituximab in patients with previously treated CLL. The Phase 2 101-09 study assessed the efficacy and safety of Zydelig in patients with iNHL who are refractory to rituximab and alkylating agents. Results of Study 116 and Study 101-09 were published in The New England Journal of Medicine in March 2014. The most commonly reported adverse reactions (incidence >=20 percent) were diarrhea, pyrexia, fatigue, nausea, cough, abdominal pain and chills. Additionally, grade 3 or 4 elevations in ALT and AST (indicators of liver function) have been observed in clinical trials of Zydelig. Grade 3 or 4 pneumonitis and Grade 3 or 4 diarrhea/colitis were also observed in some patients in the clinical trials.

Gilead Announces New Agreement with MPP on HIV Experimental Drug

Gilead Sciences Inc. announced a new agreement with the Medicines Patent Pool or MPP to expand access to the company's investigational drug tenofovir alafenamide or TAF for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval. Under the agreement, the MPP can sub-license TAF to generic drug companies in India and China, who may manufacture and distribute it in 112 developing countries. The new agreement expands on Gilead's previous licensing partnership with the MPP. In July 2011, Gilead became the first pharmaceutical company to join the MPP, and six Indian pharmaceutical companies hold MPP sub-licenses for Gilead HIV medicines. In addition to its agreement with the MPP, Gilead has direct partnerships with 11 generic manufacturers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD*:MM $1,325.00 MXN +25.00

GILD* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.06 USD -0.23
Amgen Inc $132.68 USD -0.34
AstraZeneca PLC 4,297 GBp +11.50
Bristol-Myers Squibb Co $50.04 USD -0.26
Eli Lilly & Co $62.01 USD -0.15
View Industry Companies
 

Industry Analysis

GILD*

Industry Average

Valuation GILD* Industry Range
Price/Earnings 22.9x
Price/Sales 8.9x
Price/Book 9.6x
Price/Cash Flow 20.5x
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit www.gilead.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.